Opioid analgesics

Br J Hosp Med. 1997 Feb;57(3):105-6.

Abstract

This article discusses recent developments in opioid pharmacology. Selective activity at different opioid receptors promises, but has not yet provided, a strong analgesic without opioid side-effects. The startling pharmacokinetic profile of the new esterase-metabolized intravenous opioid, remifentanil, is reflected in the rapid onset of effect and short, predictable recovery, independent of duration of infusion.

Publication types

  • Review

MeSH terms

  • Analgesics, Opioid / adverse effects
  • Analgesics, Opioid / pharmacokinetics*
  • Humans
  • Meptazinol / pharmacokinetics
  • Morphine / pharmacokinetics
  • Nalbuphine / pharmacokinetics
  • Narcotic Antagonists
  • Pain / drug therapy
  • Piperidines / adverse effects
  • Piperidines / pharmacokinetics
  • Receptors, Opioid / agonists
  • Remifentanil
  • Tramadol / pharmacokinetics

Substances

  • Analgesics, Opioid
  • Narcotic Antagonists
  • Piperidines
  • Receptors, Opioid
  • Meptazinol
  • Tramadol
  • Morphine
  • Nalbuphine
  • Remifentanil